EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study

Rika A Furuta iD, Teruhito Yasui, Takeharu Minamitani, Hiroki Akiba, Chizu Toyoda, Ryutaro Tobita, Kazuta Yasui iD, Ryota Aminaka, Mikako Masaki, Masahiro Satake iD

Transfusion · 2023

DOI: 10.1111/trf.17382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Rika A Furuta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Hepatitis B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Japan, plasma with a high concentration of Hepatitis B Virus (HBV) antibodies for hepatitis B immunoglobulin (HBIG) is almost entirely imported. We aimed to produce recombinant HBIG by isolating immunoglobulin cDNAs against the HBV surface antigen (HBsAg). Study Design and Methods B cells expressing HBsAg antibodies were obtained from blood center personnel who had been administered HB vaccine booster and then isolated by either an Epstein–Barr virus hybridoma or an antigen‐specific memory B cell sorting method. Each cDNA of the heavy and light chains of the target antibody was cloned into an IgG 1 expression vector and transfected into Expi293F cells to produce a recombinant monoclonal antibody (mAb), which was screened by ELISA and in vitro HBV neutralizing assays. The cross‐reactivity of the mAbs to normal human molecules was evaluated by ELISA and immunohistochemistry.

Results

Antibody cDNAs were cloned from 11 hybridoma cell lines and 204 HBsAg‐bound memory B cells. Three of the resulting recombinant mAbs showed stronger neutralizing activity in vitro than the currently used HBIG. All three bind to the conformational epitope(s) of HBsAg but not to human DNA or cells.

Discussion

We successfully isolated HBV‐neutralizing monoclonal antibodies from B cells collected from healthy plasma donors boosted against the HBV. To obtain an alternative source for HBIG, HBV‐neutralizing monoclonal antibodies from B cells collected from healthy plasma donors boosted against the HBV may be useful.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsHepatitis BHumansHepatitis B Surface AntigensHepatitis B virusFeasibility StudiesHerpesvirus 4, HumanHepatitis B VaccinesHepatitis B AntibodiesAntibodies, MonoclonalRecombinant ProteinsImmunoglobulins

Stichwörter der Autor:innen

antibody drughepatitis B virushuman monoclonal antibodyneutralizing antibody

Substanzen

Hepatitis B Surface AntigensHepatitis B VaccinesHepatitis B AntibodiesAntibodies, MonoclonalRecombinant Proteinshepatitis B hyperimmune globulinImmunoglobulins

Autor:innen und Institutionen

  • Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Laboratory of Infectious Diseases and Immunity, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan.
  • Laboratory of Pharmacokinetic Optimization, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Laboratory of Biopharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
  • Japanese Red Cross Kanto-Koushinetsu Block Blood Center, Tokyo, Japan.

ORCID-Profile: Rika A Furuta, Kazuta Yasui, Masahiro Satake

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Furuta, R. A., Yasui, T., Minamitani, T., Akiba, H., Toyoda, C., Tobita, R., Yasui, K., Aminaka, R., Masaki, M., & Satake, M. (2023). Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study. Transfusion. https://doi.org/10.1111/trf.17382

Vancouver

Furuta RA, Yasui T, Minamitani T, Akiba H, Toyoda C, Tobita R, et al. Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study. Transfusion. 2023. doi:10.1111/trf.17382

BibTeX
@article{Furuta2023,
  author = {Furuta, Rika A and Yasui, Teruhito and Minamitani, Takeharu and Akiba, Hiroki and Toyoda, Chizu and Tobita, Ryutaro and Yasui, Kazuta and Aminaka, Ryota and Masaki, Mikako and Satake, Masahiro},
  title = {Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study},
  journal = {Transfusion},
  year = {2023},
  doi = {10.1111/trf.17382}
}
Kostenlos starten →